Higher efficacy and complete response with administration of eribulin for recurrent squamous cell breast carcinoma: A case report

Introduction

Squamous cell carcinoma is a type of metaplastic carcinoma; metaplastic carcinoma is characterized as carcinoma of the breast ductal tissue and stratified squamous epithelial tissue followed by their consequent differentiation into bone, cartilage and osteocartilaginous tissue. It has been reported that metaplastic breast carcinoma accounts for <1% of all breast carcinomas, and it is characterized by large size, low incidence of lymphatic metastasis and high incidence of triple-negative phenotype (1–3). While chemotherapy for metaplastic carcinoma is commonly similar to that of invasive ductal carcinoma, a number of studies in the literature report a poor response to conventional chemotherapy (1,4,5). We herein report our experience with eribulin administration in a case of recurrent squamous cell carcinoma of the breast and discuss the relevant literature.

Case report

A 42-year-old woman with carcinoma of the right breast (T4N3aM0, stage IIIC) underwent mastectomy and level III axillary lymph node dissection (Fig. 1).

Figure 1. Contrast-enhanced computed tomography examination prior to therapy revealed (A) metastasis to the axillary lymph nodes and (B) skin invasion by the tumor cells.

Pathological examination revealed squamous cell carcinoma negative for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (Fig. 2). Six cycles of postoperative adjuvant chemotherapy with cyclophosphamide 500 mg/m2, epirubicin 75 mg/m2 and fluorouracil 500 mg/m2 (CEF regimen) were administered, following which an increase in the size of the ipsilateral sternal lymph nodes was observed. No other metastatic lesions were found on computed tomography (CT) scans, and the patient was subjected to lymphadenectomy with pleural drainage. Pathological examination of the resected nodes demonstrated metastatic squamous cell carcinoma. Docetaxel (75 mg/m2) was administered as adjuvant therapy; however, allergic symptoms developed, including respiratory distress and palpitations, and docetaxel was discontinued. Radiotherapy to the right thoracic wall and the right supraclavicular lymph node (60 Gy) was next administered. However, enlargement of the ipsilateral supraclavicular lymph node was observed 3 months after radiotherapy. Lymphadenopathy (lymph node enlarged to 2 cm in diameter) was identified on ultrasound examination, and fine-needle aspiration cytology confirmed the presence of metastatic squamous cell carcinoma. Fluorodeoxyglucose positron emission tomography (FDG-PET)-CT revealed accumulation in the anterior thoracic wall close to the previous surgical site (Fig. 3). Consequently, eribulin (1.4 mg/m2) was administered as initial therapy. The lymph node was not palpable at 1 month after therapy initiation, and at 3 months after chemotherapy the enlargement had completely disappeared, as demonstrated on a CT examination. No metastatic lymph node or thoracic wall FDG accumulation was observed on PET-CT 11 months after treatment initiation (Fig. 4). After 17 months of treatment, the patient remained metastasis-free. During those 17 months, no major side effects were observed although peripheral neuropathy not affecting daily life grade 1 peripheral neurotoxicity occurred.

Figure 2. Pathological examination revealed that the tumor was composed of acidophilic cells with intercellular bridges. Hematoxylin and eosin staining; magnification, ×200.

Figure 3. Accumulation of fluorodeoxyglucose in (A) a supraclavicular lymph node and (B) the anterior thorax near the previous surgical site were confirmed by positron emission tomography-computed tomography prior to the initiation of chemotherapy.

Figure 4. Positron emission tomography-computed tomography scan at 11 months after the initiation of chemotherapy confirmed the disappearance of FDG accumulation at (A) supraclavicular lymph node and (B) anterior thorax of previous surgical site.

Discussion

It is generally recommended that the protocols for the treatment of invasive ductal carcinoma of breast cancer are applied for the treatment of squamous cell carcinoma. However, poor efficacy of chemotherapy in recurrent carcinomas, including squamous cell carcinoma, has been reported to date. While previous studies have reported the use of anthracyclines and taxanes, to the best of our knowledge, there are yet no published reports on the efficacy of eribulin. We herein discuss the possible reasons for the observed effectiveness of eribulin in the treatment of metaplastic breast carcinoma.

In addition to its effectiveness against the epithelial component, it is possible that eribulin is also effective against the mesenchymal component of the carcinoma. Drug regimens including adriamycin, which is also indicated for soft tissue tumors with a mesenchymal component, have been reported to significantly prolong progression-free survival in metaplastic carcinomas compared with other regimens. Reduced incidence of hepatic metastasis has also been reported with the use of ifosfamide and etoposide, which are used for treating soft tissue tumors (6). In Study 309, eribulin was found to be effective against liposarcoma or leiomyosarcoma (7). Eribulin promotes DNA repair, the inhibition of which is characteristic of metaplastic carcinomas, and is thus considered a more effective therapeutic agent compared with adriamycin, of which the primary mechanism of action involves the inhibition of DNA synthesis.

Furthermore, in metaplastic carcinomas, tumors including squamous epithelial and sarcomatous components exhibit increased expression of TWIST and SNAIL 2 transcription factors, suggesting an association with epithelial-to-mesenchymal transition (EMT) (8,9). Reports indicate that the occurrence of EMT in cancer cells coincides with the development of resistance to various anticancer agents. Several anticancer agents have been reported to induce EMT and are considered to be involved in drug resistance. Albeit in an in vitro study, eribulin has been shown to inhibit Smad 2 and Smad 3 phosphorylation via transforming growth factor-β induction or MET inhibition. These characteristic mechanisms of action of eribulin are considered to contribute to the effectiveness of the therapy in the present case.

Acknowledgements

The authors would like to thank Shiro Sugihara for the pathological examinations and interpretations.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

YG designed the study and wrote the initial draft of the manuscript. TY contributed to the analysis and interpretation of data and assisted in the preparation of the manuscript. MK critically reviewed the manuscript. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

The study was conducted in accordance with the principles of the Declaration of Helsinki.

Patient consent for publication

This patient and her family were informed that the data from her case would be submitted for publication and provided written informed consent.

Competing interests

The authors declare that they have no competing interests.

Glossary

Abbreviations

Abbreviations:

References